The Ebola Epidemic Crystallizes the Potential of Passive Antibody Therapy for Infectious Diseases

PLoS Pathogens

Volumn 11, Issue 4, 2015, Pages

  Casadevall, Arturo ^a   Pirofski, Liise anne ^b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR; VIRUS GLYCOPROTEIN;

ANTIBIOTIC THERAPY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY RESPONSE; ANTIGEN ANTIBODY COMPLEX; ANTIGENICITY; ANTIMICROBIAL ACTIVITY; CELLULAR IMMUNITY; DISEASE ASSOCIATION; EBOLA HEMORRHAGIC FEVER; EPIDEMIC; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; MICROFLORA; NONHUMAN; PASSIVE IMMUNIZATION; PHAGOCYTOSIS; REVIEW; EPIDEMICS; HEMORRHAGIC FEVER, EBOLA; HUMAN; PROCEDURES;

EPIDEMICS; HEMORRHAGIC FEVER, EBOLA; HUMANS; IMMUNIZATION, PASSIVE;

EID: 84929484420     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1004717     Document Type: Review

References (22)

1. Casadevall A, Scharff MD, (1995) Return to the past: the case for antibody-based therapies in infectious diseases. Clin Infect Dis 21: 150–161. 7578724
2. Update: Ebola Virus Disease Epidemic—West Africa, December 2014. MMWR Morb Mortal Wkly Rep 63: 1199–1201. 25522088
3. Rybicki EP, (2014) Plant-based vaccines against viruses. Virol J 11: 205. 25465382
4. Almansa R, Eiros JM, Fedson D, Bermejo-Martin JF, (2014) Hyperimmune serum from healthy vaccinated individuals for Ebola virus disease? Lancet Glob Health 2: e686. doi: 10.1016/S2214-109X(14)70341-9 25433619
5. Casadevall A, Pirofski LA, (2012) A new synthesis for antibody-mediated immunity. Nat Immunol 13: 21–28. doi: 10.1038/ni.2184 22179281
6. Bournazos S, Klein F, Pietzsch J, Seaman MS, Nussenzweig MC, Ravetch JV, (2014) Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity. Cell 158: 1243–1253. doi: 10.1016/j.cell.2014.08.023 25215485
7. Chung AW, Ghebremichael M, Robinson H, Brown E, Choi I, Lane S, et al. (2014) Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines. Sci Transl Med 6: 228ra38.
8. Burton DR, Poignard P, Stanfield RL, Wilson IA, (2012) Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science 337: 183–186. doi: 10.1126/science.1225416 22798606
9. Rouvinski A, Guardado-Calvo P, Barba-Spaeth G, Duquerroy S, Vaney MC, Kikuti CM, et al. (2015) Recognition determinants of broadly neutralizing human antibodies against dengue viruses. Nature.
10. Wang TT, Tan GS, Hai R, Pica N, Petersen E, Moran TM, et al. (2010) Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins. PLoS Pathog 6: e1000796. doi: 10.1371/journal.ppat.1000796 20195520
11. Bakker AB, Python C, Kissling CJ, Pandya P, Marissen WE, Brink MF, et al. (2008) First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity. Vaccine 26: 5922–5927. doi: 10.1016/j.vaccine.2008.08.050 18804136
12. Lowy I, Molrine DC, Leav BA, Blair BM, Baxter R, Gerding DN, et al. (2010) Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 362: 197–205. doi: 10.1056/NEJMoa0907635 20089970
13. Sobarzo A, Groseth A, Dolnik O, Becker S, Lutwama JJ, Perelman E, et al. (2013) Profile and persistence of the virus-specific neutralizing humoral immune response in human survivors of Sudan ebolavirus (Gulu). J Infect Dis 208: 299–309. j doi: 10.1093/infdis/jit162 23585686
14. Macneil A, Reed Z, Rollin PE, (2011) Serologic cross-reactivity of human IgM and IgG antibodies to five species of Ebola virus. PLoS Negl Trop Dis 5: e1175. doi: 10.1371/journal.pntd.0001175 21666792
15. Robbins JB, Schneerson R, Szu SC, (1995) Perspective: Hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J Infect Dis 171: 1387–1398. 7769272
16. Casadevall A, Pirofski LA, (2003) Antibody-mediated regulation of cellular immunity and the inflammatory response. Trends Immunol 24: 474–478. 12967670
17. Greenough TC, Babcock GJ, Roberts A, Hernandez HJ, Thomas WD, Jr.Coccia JA, et al. (2005) Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice. J Infect Dis 191: 507–514. 15655773
18. Luke TC, Casadevall A, Watowich SJ, Hoffman SL, Beigel JH, Burgess TH, (2010) Hark back: passive immunotherapy for influenza and other serious infections. Crit Care Med 38: e66–e73. doi: 10.1097/CCM.0b013e3181d44c1e 20154602
19. Mupapa K, Massamba M, Kibadi K, Kuvula K, Bwaka A, Kipasa M, et al. (1999) Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. J Infect Dis 179 Suppl 1: S18–S23. 9988160
20. Fedson DS, (2014) A Practical Treatment for Patients With Ebola Virus Disease. J Infect Dis.
21. Butler D, (2014) Ebola raises profile of blood-based therapy. Nature 517: 9–10.
22. Reichert JM, (2013) Which are the antibodies to watch in 2013? MAbs 5: 1–4. doi: 10.4161/mabs.22976 23254906